HERS

(redirected from Heart and Estrogen/Progestin Replacement Study)
AcronymDefinition
HERSHome Energy Rating System
HERSHeart and Estrogen/Progestin Replacement Study
HERSHighway Electrical Registration Scheme (UK)
HERSHelicopter Rappel Spotter (various organizations)
HERSHigh Energy Range Spectrometer
HERSHyperion Energy Recovery System
HERSHigher Education Resources Services
HERSHysterectomy Education Resources and Services (Foundation)
HERSHelicopter Expedient Refueling System
HERSHead End Ring Switching (Protocol)
HERSHydrogeochemical Engineering and Remediation of Soil (Lab; Technical University of Crete)
References in periodicals archive ?
Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).
Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification
Preventive therapies are underprescribed for postmenopausal women with preexisting coronary heart disease, according to data from the Heart and Estrogen/Progestin Replacement Study Research Group.
CHD prevention underused in older, high-risk women. (Statins, [beta]-Blockers)
But in the two large randomized trials to date--the Heart and Estrogen/Progestin Replacement Study (HERS) and the Estrogen Replacement and Atherosclerosis (ERA) trial--HRT showed no clinical or angiographic benefit.
No HRT Cardioprotection in Diabetic Women
Nevertheless, an HRT-stimulated rise in MDL cholesterol levels in the Heart and Estrogen/Progestin Replacement Study they noted, produced no effect on coronary heart disease in women with established disease.
Certain genes may help HRT raise HDL, cut coronary risk. (May be able to predict HRT Response)
The Heart and Estrogen/Progestin Replacement Study (HERS) was designed to study the effect of HRT in women, controlling by randomization for all these biases and other unknown confounders.
PRO & CON
Results from the Heart and Estrogen/Progestin Replacement Study showed a 50% excess of cardiovascular events in women with a history of cardiovascular disease during the first year that they received estrogen plus progestin.
No Excess CV Events Seen With Raloxifene Use
Acronyms browser ?
Full browser ?